clinical trial · NCT06690775
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
TORL Biotherapeutics, LLC·phase2·recruiting·n = 230
Epithelial Ovarian CancerPrimary PeritonealFallopian Tube CancerEndometrioid Ovarian CancerTORL-1-23TORL-1-23TORL-1-23Pegfilgrastim (drug)
brief summary
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
started
Nov 20, 2024
primary completion
Oct 1, 2027
completion
Dec 1, 2027
last updated
Dec 23, 2025
official title
Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol